	US 12,240,882 B2
	Fusion proteins comprising an engineered knottin peptide and uses thereof
Jennifer R. Cochran, Stanford, CA (US); Douglas S. Jones, Newton, MA (US); Mihalis S. Kariolis, San Mateo, CA (US); and Ping-Chuan Tsai, Fremont, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Nov. 14, 2022, as Appl. No. 18/055,297.
Application 18/055,297 is a continuation of application No. 17/066,167, filed on Oct. 8, 2020, granted, now 11,498,952.
Application 17/066,167 is a continuation of application No. 13/883,216, granted, now 10,844,106, issued on Nov. 24, 2020, previously published as PCT/US2011/059599, filed on Nov. 7, 2011.
Claims priority of provisional application 61/411,350, filed on Nov. 8, 2010.
Prior Publication US 2023/0227523 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/37 (2006.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/81 (2006.01)

CPC C07K 14/705 (2013.01) [C07K 14/43518 (2013.01); C07K 14/47 (2013.01); C07K 14/4702 (2013.01); C07K 14/475 (2013.01); C07K 14/71 (2013.01); C07K 14/81 (2013.01); C07K 14/8121 (2013.01); C07K 2319/00 (2013.01)]

14 Claims

10. A pharmaceutical composition, comprising:

(i) a dimer comprising a first recombinant soluble fusion protein and a second recombinant soluble fusion protein, wherein the first recombinant soluble fusion protein and the second recombinant soluble fusion protein each comprise:

(a) an EETI-II knottin polypeptide domain having therein a binding loop comprising an RGD-containing non-native sequence, wherein the non-native sequence mediates binding to one or more of (a) alpha v beta 3 integrin, (b) alpha v beta 5 integrin, and (c) alpha 5 beta 1 integrin; and

(b) an antibody Fc domain,

wherein the first fusion protein and the second fusion protein are dimerized to each other via their antibody Fc domains; and

(ii) a pharmaceutically-acceptable carrier.